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Abstract Abiraterone acetate (CB 7630; CB7630; JNJ-212082), the 3b-acetate pro-
drug of abiraterone, is structurally related to ketoconazole and is being
developed by Cougar Biotechnology as a hormonal therapy for advanced
prostate and breast cancers. As a selective inhibitor of adrenal androgens,
it is thought to be a safer product than existing second-line hormonal thera-
pies. This review discusses the key development milestones and therapeutic
trials of this drug.
1. Introduction
Abiraterone acetate is structurally related to
ketoconazole and is the 3b-acetate prodrug of
abiraterone. Abiraterone acetate is being devel-
oped by Cougar Biotechnology (a subsidiary of
Johnson & Johnson) as a hormonal therapy for
advanced prostate and breast cancers. This orally
active agent was first synthesized at the Insti-
tute of Cancer Research (ICR) in the UK as part
of a BTG-funded program, and subsequently li-
censed to Cougar Biotechnology. It irreversibly
inhibits the steroidal enzyme 17a-hydroxylase/
C17-20 lyase (also known as cytochrome P450
[CYP]17A1 or P450c17), a CYP complex that is
involved in testosterone production. Phase III
trials in men with castration-resistant prostate
cancer (CRPC) and a phase I/II trial in advanced
breast cancer are underway.
Abiraterone acetate is believed to have potential
advantages over existing second-line hormonal
therapies in patients with prostate cancer because
it selectively inhibits adrenal androgens, making
the product safer to use. Cougar Biotechnology
has stated that the drug has a potential role as a
second-line hormonal therapy for patients with
advanced prostate cancer resistant to first-line
hormonal treatment or first-line docetaxel-based
chemotherapy.[1]
In July 2009, Cougar Biotechnology became a
wholly owned subsidiary of Johnson & Johnson.[2]
1.1 Company Agreements
If approved, abiraterone acetate will be com-
mercialized and marketed by Ortho Biotech in
the US and by Janssen Pharmaceuticals in other
countries worldwide.[3]
Cougar Biotechnology itself licensed the pro-
duct from BTG plc. in April 2004. This agreement
granted Cougar Biotechnology exclusive worldwide
rights to develop and commercialize abiraterone
acetate, while BTG plc. received an upfront cash
payment and is entitled to milestones payments and
royalties on sales.[4]
Boehringer Ingelheim had an exclusive option
to license the development and marketing rights
to abiraterone acetate. However, the company
chose not to exercise the option.
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1.2 Key Development Milestones
1.2.1 Prostate Cancer
Cougar Biotechnology expects to file market-
ing applications for abiraterone acetate in the
US and Europe before the end of 2010, based on
interim data from the phase III COU-AA-301
trial (NCT00638690). The randomized, placebo-
controlled trial is investigating abiraterone ace-
tate in combination with low-dose prednisone or
prednisolone in 1195 patients with metastatic
CRPC that has progressed following treatment
with one or two chemotherapy regimens, at least
one of which was docetaxel.[5] In September 2010,
this trial was unblinded after a recommendation
from the Independent Data Monitoring Commit-
tee, after a prespecified interim analysis showed a
statistically significant improvement in overall sur-
vival and an acceptable safety profile. It was also
recommended that patients receiving placebo be
offered abiraterone acetate. Cougar Biotechnology
planned to initiate an early access program in the
US in October 2010, with expansion to other sites
in the months following.[3,6,7]
Another phase III trial is underway, evaluating
abiraterone acetate plus prednisone or placebo
plus prednisone in patients with metastatic CRPC
from North America, Europe, and Australia
(NCT00887198). The primary endpoints are
progression-free survival and overall survival.[5,8,9]
Patient enrollment was completed in May 2010.
A phase I/II trial examined daily oral abiraterone
acetate as a second-line therapy in chemotherapy-
naive CRPC progressing despite treatment with
luteinizing hormone-releasing hormone (LHRH)
analogs and multiple other hormonal therapies
(NCT00473746). The study was conducted at the
University of California, San Francisco (UCSF),
USA, Comprehensive Cancer Center, with prelim-
inary results presented.[1,10,11] Johnson & Johnson,
Cougar Biotechnology, andUCSF are also conduc-
ting a phase II clinical trial to evaluate the efficacy of
abiraterone acetate in approximately 46 patients
with CRPC who have experienced disease pro-
gression on ketoconazole (NCT01199146).
In November 2009, Cougar Biotechnology
initiated a phase II study of abiraterone acetate as
a neo-adjuvant, in combination with prednisone
and a LHRH analog, in approximately 66 pa-
tients with prostate cancer (NCT01088529).
Cougar Biotechnology and theM.D. Anderson
Cancer Center are conducting an observational
study of continuous oral dosing of abiraterone
acetate in 60 patients with CRPC, evaluating the
effect of the drug on levels of testosterone and
DHT in bone marrow plasma (NCT00544440).
Preliminary results were reported from a phase
II study evaluating the anti-tumor efficacy and
safety of abiraterone acetate in combination with
prednisone in 58 patients with advanced prostate
cancer who had failed androgen deprivation and
docetaxel-based chemotherapy in the US and
UK (NCT00485303).[1,12] Positive results were
presented from a phase II trial that evaluated
abiraterone acetate in 33 patients with advanced
prostate cancer that had failed first-line chemo-
therapy with docetaxel (NCT00474383).[1,13]
In December 2006, Cougar Biotechnology ini-
tiated the phase II portion of a phase I/II study that
evaluated daily dosing of abiraterone acetate as a
second-line hormonal treatment for patients with
chemotherapy-naive hormone-refractory prostate
cancer and who have rising prostate specific antigen
(PSA) levels (NCT00473512). A total of 44 patients
were enrolled at trial sites in the UK. Interim data
from the phase I/II study have been reported.[14,15]
In June 2010, Janssen Pharmaceutica initiated
an open-label phase I trial to assess the pharma-
codynamics and safety of abiraterone acetate in
patients with CRPC (NCT01186484). The trial
will enroll 18 patients in Japan.[16]
A phase I study to determine the effect of abir-
aterone acetate and prednisone on the heart is
underway in the US and Canada (NCT00910754).
A phase I pharmacokinetic study compared the
tablet and capsule formulations of abiraterone
acetate in approximately 40 patients with prostate
cancer (NCT00600535).
The ICR and BTG completed three phase I
trials of abiraterone acetate. The first phase I
single-dose study was conducted in 16 patients
with prostate cancer, and demonstrated suppres-
sion of testosterone to target levels without any
serious adverse events. A second single-dose study
in four patients with normal levels of testosterone
showed significant suppression of testosterone le-
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vels and good tolerability. A third multiple-dose
study showed complete suppression of testosterone
synthesis in six patients.[17]
1.2.2 Breast Cancer
Cancer Research UK is enrolling approx-
imately 74 female patients in a phase I/II, open-
label, dose-escalating study, evaluating the safe-
ty, endocrine effects, and anti-tumor activity of
abiraterone acetate in estrogen or androgen re-
ceptor positive metastatic breast cancer, who
have progressed on at least two lines of hormonal
therapies, such as aromatase inhibitors and ta-
moxifen (NCT00755885).[18,19]
1.3 Patent Information
Abiraterone acetate is covered by two US
patents (No. 5 604 213 and 5 618 807), which ex-
pire in 2014. Patent applications have also been
filed in other territories.
2. Scientific Summary
2.1 Pharmacokinetics
The tablet and capsule formulations of abir-
aterone were assessed in a phase I crossover study
of patients with prostate cancer. Similar max-
imum plasma concentration (Cmax) and area un-
der the concentration-time curve (AUC) values
were obtained for both formulations and in both
cases the values were higher in the fed state
compared with the fasted state. Cmax values were
1469 (fed), 286 (fasted), and 1573 (fed), 324 (fasted),
and AUC values were 10978 (fed), 3249 (fasted),




Phase III : Treatment with abiraterone acetate
was associated with an increase in the frequency
of mineralocorticoid-related adverse events, com-
pared with placebo, in the phase III COU-AA-301
trial. The trial randomized 1195 patients with meta-
static, castrate-resistant prostate cancer to treatment
with either abiraterone acetate or placebo, in com-
bination with low-dose prednisone or prednisolone.
In the abiraterone and placebo groups, fluid re-
tention occurred in 30.5% versus 22.3% of patients,
respectively, and hypokalemia occurred in 17.1%
versus 8.4% of patients. Grade 3/4 hypokalemia was
reported in 3.8% versus 0.8% of patients and grade
Table I. Features and properties
Alternate names CB 7630; CB7630; JNJ-212082
Originator The Institute of Cancer Research
Licensee(s) Cougar Biotechnology
Highest development phase III (Australia, Canada, Europe, USA)
Active development indications Breast cancer, prostate cancer
Class Androstenols, small molecules
Mechanism of action CYP17A1 protein inhibitors
Chemical name 17-(pyridin-3-yl)androsta-5,16-dien-3b-yl acetate
Molecular formula C26 H33 N O2
CAS registry number 154229-18-2
Route of administration PO
Pharmacodynamics Inhibits androgen biosynthesis without suppressing corticosterone production in mice; suppresses
testosterone to castration levels in patients with prostate cancer
ATC codes
WHO ATC code L02B-B (anti-androgens)
EphMRA ATC code L2B2 (cytostatic anti-androgens)
Adverse events
Occasional Hypertension, hypokalemia, edema
Rare Cardiovascular disorders, liver dysfunction
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3/4 hypertension occurred in 1.3% versus 0.3% in the
abiraterone acetate and placebo groups, respective-
ly. Cardiac disorders and liver function test abnor-
malities were also more frequent in the abiraterone
acetate group than the placebo group (12.5% vs
9.4% and 10.4% vs 8.1%, respectively). These ad-
verse events were responsive to medical treatment.[3]
Phase II : Interim results indicated that abir-
aterone acetate (up to 2000 mg/day) was well
tolerated with minimal toxicity in chemotherapy-
naive patients with CRPC in a phase I/II study.[14]
Phase I : Abiraterone acetate was well tolerated
at oral doses as high as 2000mg/day withminimal
toxicity in 18 chemotherapy-naive patients with
CRPC in a phase I study. Furthermore, no dose-
limiting toxicity was observed.[21,22]
Animal Toxicology : The effects of abiraterone
acetate, abiraterone, and CB 7627 on WHT mice
were compared with castration and the two clin-
ically active compounds, ketoconazole and fluta-
mide. Flutamide and castration caused significant
reductions in the weight of the ventral prostate and
seminal vesicles. Abiraterone acetate, abiraterone
or CB 7627 once daily for 3 weeks caused sig-
nificant reductions in the weights of the ventral
prostate, seminal vesicles, kidneys, and testes; ke-
toconazole caused no reductions.[23]
2.3 Pharmacodynamics
2.3.1 Cancer
Clinical Studies : Interim results from a phase
II trial in 16 evaluable patients with CRPC who
had progressive disease despite treatment with
LHRHanalogs andmultiple other therapies showed
a decline in both serum and bone marrow tes-
tosterone levels to below detectable levels in all
patients. Patients with depleted baseline bone
marrow testosterone levels appeared to progress
earlier when treated with abiraterone acetate com-
pared with measurable baseline bone marrow
testosterone levels. Further examination of bone
marrow biopsies in patients treated with abir-
aterone acetate revealed both overexpression of
androgen receptor and CYP17.[12]
Preliminary results from a phase II trial
(COU-AA-002) in patients with chemotherapy-
naive CRPC treated with abiraterone acetate in
combination with prednisone showed a decline
in PSA levels of >30% in 24 of 31 evaluable
patients (77%). A decline of >50% was seen in
71% of patients and 26% of patients experi-
enced a decline of PSA levels >90%. The median
time to progression was not reached, and patients
were continued to be treated for 10 or more
months.[24]
Preliminary results from a phase II trial
(COU-AA-BMA) in patients with CRPC who
had progressive disease despite treatment with
LHRH analogs and other therapies, showed that
treatment with abiraterone acetate in combina-
tion with prednisone resulted in a decline in PSA
levels of >50% in 24 patients (48%). Declines of
>90% were seen in six patients (12%). Further-
more, a decline in both serum and bone marrow
testosterone levels to below detectable levels was
seen in all patients in the trial.[24]
In a phase I trial in three non-castrated
patients with prostate cancer given abiraterone
acetate (500mg/day) for 12 days, testosterone le-
vels were suppressed to <2 nmol/L, but remained
>0.7nmol/L. A second three-patient non-castrated
cohort, treated with 800mg/day for 12 days, dem-
onstrated suppression of testosterone to <0.7nmol/L
in two patients, with a nadir of 1.7nmol/L in the
third patient.[25]
In the two single-dose clinical studies, four of
six castrated patients treated with a single-dose of
abiraterone acetate 500mg achieved suppression
of testosterone to levels <0.14 nmol/L. Patients
treated at the 500 and 800mg level experienced
suppression of testosterone to castrate levels
(<2.0 nmol/L). Among the patients treated with
800mg/day, two of three had complete sup-
pression of testosterone down to levels compar-
able with those typically seen in patients treated
with LHRH agonists (<0.7 nmol/L).[26]
Preclinical Studies : Abiraterone acetate re-
duced plasma testosterone levels to £0.1 nmol/L,
despite a 3- to 4-fold increase in the plasma level
of luteinizing hormone in mice. Adrenal weights
were unchanged following treatment with abir-
aterone acetate or CB 7627, but were markedly
increased following ketoconazole, indicating no
inhibition of corticosterone production by these
steroidal compounds.[23]
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Phase III : Abiraterone acetate increased sur-
vival by 36%, compared with placebo, according
to the results of a prespecified interim analysis of
the COU-AA-301 trial. The trial included 1195
patients with metastatic, CRPC who had pre-
viously received one or two chemotherapy regi-
mens, at least one of which contained docetaxel.
Patients were randomized to receive abiraterone
acetate or placebo, in addition to low-dose pred-
nisone or prednisolone. The median overall sur-
vival duration was 14.8 months in the abiraterone
group versus 10.9 months in the placebo group.
The risk of death was reduced by 35% (p < 0.001
versus placebo). Abiraterone acetate also signifi-
cantly increased the time to disease progression
and PSA-response rate compared with placebo.[3]
Phase II : Radiologic disease control was ach-
ieved in 28 of 33 (85%) evaluable patients, with
partial responses in nine patients (27%) and stable
disease in 19 patients (58%), according to pre-
liminary results of a phase II trial (COU-AA-002)
of abiraterone acetate plus prednisone in che-
motherapy-naive patients with CRPC who had
progressive disease despite treatment with LHRH
analogs and other hormonal therapies. Patients
received abiraterone acetate and prednisone once
daily. After 12 weeks, a decline in levels of PSA
of >30%was noted in 26 patients (79%), a PSA de-
cline of >50% in 24 patients (73%), and a PSA
decline of >90% in ten patients (30%). The median
time to PSA progression was 337 days.[1,12,24]
Preliminary results from a phase II trial
(COU-AA-BMA) in patients with CRPC who
had progressive disease despite treatment with
LHRH analogs and other therapies showed that
four patients (19%) treated with abiraterone acetate
in combinationwith prednisone showed an improve-
ment in their bone scan after 6 months of treatment.
A stable bone scan was seen in 15 patients (71%).[24]
Preliminary results from a phase II trial
(COU-AA-004) of abiraterone acetate in patients
with metastatic CRPC have been reported. Abi-
raterone acetate in combination with prednisone
was administered orally, once daily, to patients
with CRPC who had progressive disease despite
prior treatment with androgen deprivation therapy
and first-line docetaxel-based chemotherapy.
Of the 58 evaluable patients who have been
treated so far, abiraterone acetate was well tolerated
with only minimal toxicity. After 12 weeks, 20 pa-
tients (34%) experienced a confirmed decline in
PSA levels of >50%. Of the 31 patients who had
not received prior treatment with ketoconazole,
13 patients (42%) experienced a confirmed de-
cline in PSA levels of >50%. Furthermore, of the
27 patients who had been previously treated with
ketoconazole, seven patients (26%) experienced a
confirmed decline in PSA levels of >50%. The
median time to PSA progression was estimated to
be 198 days and 99 days in patients who had not
been previously treated with ketoconazole and in
those who had, respectively. Of the 18 patients
with measurable tumor lesions, 11 patients (61%)
showed stable disease and three patients (17%)
had confirmed partial radiologic responses (by
RECIST criteria).[1,27,28]
In a phase I/II trial (COU-AA-001) of abir-
aterone acetate in patients with hormone-refractory,
chemotherapy-naive prostate cancer, abiraterone
acetate was administered orally, once daily, to pa-
tients who had progressive disease despite treat-
ment with LHRH analogs and multiple other
hormonal therapies. At the time of PSA pro-
gression on abiraterone acetate, dexamethasone
was added to abiraterone acetate to see if it could
overcome the resistance to abiraterone acetate.
Of the 54 evaluable patients from the study,
38 patients (70%) experienced a confirmed de-
cline in PSA levels of greater than 50% while re-
ceiving abiraterone acetate as a monotherapy.
For the 54 evaluable patients in the trial, the
median time to PSA progression while the pa-
tients were receiving abiraterone acetate alone
was estimated to be 231 days (33 weeks). Thus far
in the trial, 30 of the 54 patients have been treated
with dexamethasone in addition to abiraterone
acetate, at the time of PSA progression. Nine
(30%) of these 30 patients have experienced a
confirmed partial decline in PSA levels of greater
than 50% when treated with the combination of
abiraterone acetate and dexamethasone after
PSA progression on abiraterone acetate alone.
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Table II. History
Event date Update type Comment Update date
11 October 2010 Scientific update Efficacy and adverse events data from a phase III trial in prostate
cancer presented in a late-breaking presentation at the 35th
Congress of the European Society for Medical Oncology (ESMO-
2010)[3]
13 October 2010
30 June 2010 Phase change Phase I clinical trials in prostate cancer in Japan (PO) 5 October 2010
21 May 2010 Trial update Cougar Biotechnology completes enrollment in a phase III trial in
metastatic castration-resistant prostate cancer in North America,
Europe, and Australia
4 June 2010
1 November 2009 Phase change Phase II clinical trials in prostate cancer in the US (PO) 26 March 2010
10 July 2009 Company name changes Cougar Biotechnology has been acquired by Johnson & Johnson 13 July 2009
1 June 2009 Scientific update Preliminary efficacy data from three phase II trials in prostate
cancer presented at the 45th Annual Meeting of the American
Society of Clinical Oncology (ASCO-2009)[1]
11 June 2009
30 April 2009 Trial update Cougar Biotechnology initiates a phase III trial in chemotherapy-
naive castration-resistant prostate cancer in North America,
Europe, and Australia[8]
5 May 2009
28 February 2009 Scientific update Interim efficacy and pharmacodynamics data from two phase II
trials in prostate cancer released by Cougar Biotechnology[24]
3 March 2009
11 February 2009 Regulatory status Cougar Biotechnology and US FDA agree on Special Protocol
Assessment for phase III trial of abiraterone acetate in castration-
resistant, chemotherapy-naive prostate cancer[9]
12 February 2009
21 November 2008 Phase change Phase I/II clinical trials in advanced breast cancer in the UK (PO) 24 November 2008
18 October 2008 Scientific update Interim efficacy and pharmacodynamics data from a phase II trial in
prostate cancer released by Cougar Biotechnology[12]
22 October 2008
23 July 2008 Scientific update Efficacy data from a phase I trial in prostate cancer released by
BTG plc.[17]
23 July 2008
15 July 2008 Phase change Phase III clinical trials in prostate cancer in Australia (PO) 15 July 2008
15 July 2008 Phase change Phase III clinical trials in prostate cancer in Canada (PO) 15 July 2008
15 July 2008 Phase change Phase III clinical trials in prostate cancer in Europe (PO) 15 July 2008
3 June 2008 Scientific update Efficacy data from a phase I and phase II trials and
pharmacokinetics data from a phase I trial in prostate cancer
presented at the 44th Annual Meeting of the American Society of
Clinical Oncology (ASCO-2008)[20,27,28]
13 June 2008
29 April 2008 Phase change Phase III clinical trials in prostate cancer in the US (PO) 29 April 2008
16 February 2008 Scientific update Efficacy data from a phase I trial in castration resistant prostate
cancer presented at the 2008 ASCO Genitourinary Cancers
Symposium[10]
19 February 2008
31 July 2007 Phase change Phase I clinical trials in prostate cancer in the US (PO) 9 November 2010
30 June 2007 Phase change Phase II clinical trials in prostate cancer in the US (PO) 22 November 2007
18 June 2007 Scientific update Data presented at the 43rd Annual Meeting of the American Society
of Clinical Oncology (ASCO-2007) added to the adverse events
and cancer therapeutic trials sections[14]
29 June 2007
9 May 2007 Scientific update Data presented at the 98th Annual Meeting of the American
Association for Cancer Research (AACR-2007) added to the
Cancer therapeutic trials section[29,30]
9 May 2007
29 December 2006 Phase change Phase II clinical trials in prostate cancer in the UK (PO) 29 December 2006
12 December 2006 Scientific update Updated results from a phase I trial in patients with advanced
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Themedian time to PSA progression was estimated
to be 399 days (57 weeks). Of the 29 evaluable
patients with measureable tumor lesions, treat-
ment with abiraterone acetate resulted in partial
radiologic responses in 15 patients (52%), with
eight patients (28%) demonstrating ongoing stable
disease as assessed by an independent radiologic
review blinded to outcome data.[27]
Radiologic disease control was achieved in 31
of 47 (66%) evaluable patients with measurable
tumor lesions, with partial radiologic response in
six patients (13%) and stable disease in 25 pa-
tients (53%), according to results from a phase II
trial (COU-AA-003) of once-daily abiraterone
acetate in patients with CRPC who had progres-
sive disease despite prior treatment with androgen
deprivation therapy and first-line docetaxel-based
chemotherapy. After 12 weeks, a decline in PSA
levels of >30%was observed in 24 patients (51%), a
PSA decline of >50% in 19 patients (40%), and a
PSA decline of >90% in six patients (13%).[1,29]
Interim results indicated that abiraterone ace-
tate (up to 2000 mg/day, orally) provided clinical
benefits in chemotherapy-naive patients with
CRPC in a phase I/II study. Among 34 patients
evaluable for response, 22 patients (65%) had a
confirmed decline in PSA levels of >50%, where
10 of 34 patients (29%) had a decline in PSA le-
vels of >90%. Among 20 evaluable patients with
measurable tumor lesions, 11 patients (55%) had
partial radiologic responses, where seven patients
showed durable stable disease and three patients
had regression of bone lesions. Several abirater-
one acetate recipients also had improvement in
pain and a marked reduction in opiate use. Cir-
culating tumor cells (CTC) were detected in 16 of
34 patients and changes in CTC counts were
shown to correspond with changes in PSA.[14,30]
Phase I : During a phase I dose-ranging trial
(COU-AA-002), abiraterone acetate was admin-
istered once-daily to chemotherapy-naive patients
with CRPC who had progressive disease despite
treatment with LHRH analogs and multiple
other hormonal therapies. Overall, 27 of the 30
evaluable patients (90%) experienced a decline in
PSA levels while receiving abiraterone acetate,
with 16 of 30 patients (53%) experiencing a greater
than 50% decline in PSA levels. Of the 11 patients
in the trial who had not received prior ketoconazole
treatment, six patients (55%) experienced a greater
Table II. Contd
Event date Update type Comment Update date
9 October 2006 Scientific update Interim results from a phase I trial in patients with advanced
prostate cancer have been added to the adverse events and cancer
therapeutic trials sections[22]
11 October 2006
11 July 2006 Phase change Phase I clinical trials in prostate cancer in the US (PO) 12 July 2006
2 February 2006 Regulatory status Cougar Biotechnology has filed an IND with the US FDA to conduct
a phase I trial for prostate cancer; the IND filing has been accepted
7 February 2006
14 December 2005 Phase change Phase I/II clinical trials for prostate cancer in the UK (PO) 4 May 2006
5 October 2005 Regulatory status Cougar Biotechnology has filed a CTA with the MHRA to conduct a
phase I/II trial in the UK for prostate cancer; the CTA filing has been
accepted
7 October 2005
22 February 2005 Scientific update Data from a media release have been added to the cancer
pharmacodynamics section[25]
22 February 2005
27 October 2004 Scientific update Data from a media release have been added to the cancer
pharmacodynamics section[26]
27 October 2004
22 April 2004 Licensing status Abiraterone acetate has been licensed to Cougar Biotechnologies
worldwide
22 April 2004
1 March 2001 Licensing status Abiraterone acetate is available for licensing
(http://www.btgplc.com)
1 March 2001
18 December 1997 Phase change Phase I clinical trials for prostate cancer in the UK (PO) 18 December 1997
20 February 1996 Phase change Phase I clinical trials for cancer in the UK (PO) 20 February 1996
10 May 1995 Phase change Preclinical development for cancer in the UK (PO) 10 May 1995
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than 50% decline in PSA levels as a result of
treatment with abiraterone acetate. Additionally,
10 (53%) of the 19 patients who had previously
received ketoconazole experienced a 50% or greater
decline in PSA while receiving abiraterone ace-
tate. Moreover, 9 (56%) of 16 patients who had
previously responded to ketoconazole also ex-
perienced a greater than 50% decline in PSA
while being treated with abiraterone acetate and
one (33%) of the three patients who had no res-
ponse to ketoconazole experienced a greater than
50% decline in PSA while being treated with
abiraterone acetate. The median time to progres-
sion in the patients who had previously received
ketoconazole was 21 weeks.[10,27]
Once-daily dosing of oral abiraterone acetate
displayed clinical benefits as a second-line hor-
monal therapy in patients with CRPC in a phase I
study (n= 18). Of the 13 patients that were evalu-
able for antitumor activity, 9 of 13 (69%) and 6 of
13 (46%) patients had confirmed reductions in PSA
levels of >50% and >90%, respectively. CTC were
detected in 6 of 14 patients and changes in CTC
counts correlated with changes in PSA. Among
eight evaluable patients with measurable tumor le-
sions, abiraterone acetate therapy yielded partial
radiologic responses in 5 of 8 (63%) patients. In
addition, individual patients treated with abirater-
one acetate experienced radiographic regression of
bone metastases and improvement in pain.[21,22]
Abiraterone acetate significantly reduced tumor
volume and reduced PSA levels in 70–80% of
chemotherapy-naive men with advanced prostate
cancer resistant to multiple hormone therapies.[17]
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Table III. Forecasts
InThought Probability of Approvala
Indication Approval Date Estimate inThought Approvability Index Last Update
Prostate cancer NE 66% (NYR) 21 Jul 2009
a The Wolters Kluwer Health Approvability Index is a dynamic tool that assesses the progress of a drug candidate through clinical
development, evaluating strength of clinical data and trial design, benchmarked against historical parameters and likelihood to maintain
forward momentum. Points are assigned for specific line items relating to safety, efficacy, and other factors in each phase of clinical
development. Possible points total 100 upon drug approval, and are allocated in each phase according to the historical approval rate of
similar drugs, such that the current points of a drug relate to its probability of approval. In addition, a letter grade is assigned and reflects the
momentum of a drug candidate in its current phase, with ‘A’ indicating significantly above average/likely to progress, ‘C’ indicating average,
and ‘F’ indicating significantly below average/unlikely to progress. ‘NYR’ stands for ‘Not Yet Rated,’ indicating that the probability of
approval is based on historical approval rates for similar drugs according to indication, molecule type, novelty, and phase, but without
analyses of clinical data, trial design, and other factors specific to the individual agent.
NE = no estimate.
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